FDA approves drug to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
Read more: FDA Approves New indication for Drug to Treat Neurogenic Detrusor Overactivity in Pediatric Patients